KSI-501's DAYBREAK Phase 3 readout will determine whether Kodiak's bispecific platform extends beyond Zenkuda's DR success into the crowded wet AMD market

Kodiak Sciences is a clinical-stage company developing KSI-501 for wet age-related macular degeneration, which is not yet approved.

KSI-501 is a bispecific antibody targeting wet AMD, tested in DAYBREAK Phase 3 across approximately 690 subjects. The thesis resolves on whether DAYBREAK meets its primary endpoint, validating the bispecific TIE-2/VEGF mechanism against anti-VEGF monotherapy in a registrational setting. The primary competitive threat is the entrenched wet AMD standard of care — Eylea HD (aflibercept 8mg) and faricimab (Vabysmo) — both offering durability advantages that any new entrant must demonstrably exceed.